STTK Shattuck Therapeutics: רווח נקי למניה ב-12 החודשים האחרונים

Shattuck Labs, Inc. (STTK) develops protein immune stimulants for cancer therapy, aiming to outperform current analogs. Operations rely on green chemistry principles and energy efficiency within laboratories. This EPS (TTM) price chart illustrating value trends shows a figure of 50.50. Prospects are linked to the digitalization of accounting and strict adherence to safety standards during the creation of innovative drugs, which minimizes the risk of harmful emissions.
STTK (Shattuck Labs Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The premium pricing power of Shattuck Labs, Inc. (STTK) in solid tumor therapy is directly reflected in the comparable annual growth of EPS TTM, which captures the dynamics of net income per share. This indicator measures the growth rate of the business's fundamental value over a rolling year, allowing investors to determine whether the current capitalization is justified by real scaling of returns or if the asset is overvalued by the market.